Post job

Explore jobs

Find specific jobs

Explore careers

Explore professions

Best companies

Explore companies

Orbsen Therapeutics Leadership

Zippia score 3.9
OverviewRevenue

Reviews

CEO & Executives

Orbsen Therapeutics executives

Work at Orbsen Therapeutics?
Share your experience

Rate Orbsen Therapeutics' leadership communication with employees.

Zippia waving zebra
Name & TitleBio
Larry A. Couture

Board Member

Larry A. Couture's LinkedIn

Prof Frank Barry

Board Member

Stephen Elliman

Chief Scientific Officer

Stephen Elliman's LinkedIn

I am an avid stromal cell therapy developer with a habit of sitting up to 3am writing EU grants. I am passionate about developing the safest, defined and most effective stromal cell immunotherapies for patients suffering with immune mediated inflammatory diseases with unmet need. To enable this, we've developed ORBCEL at Orbsen Therapeutics.

ORBCEL is a next-gen stromal cell therapy that can be isolated from marrow or umbilical cord and ORBCEL is currently being validated and tested by 20 rigorous, independent academic research investigators around Europe and UK - as part of 6 EU, Innovate UK and Wellcome Trust funded programs.

Prof Timothy O’Brien

Board Member

Jack Kavanaugh

Board Member

Gerry Cuddy

Board Member

James F.x. Fahy

Board Member

Robert M. Snukal

Board Member

Do you work at Orbsen Therapeutics?

Does leadership effectively guide Orbsen Therapeutics toward its goals?

Orbsen Therapeutics jobs

Orbsen Therapeutics founders

Name & TitleBio
Larry A. Couture

Board Member

Larry A. Couture's LinkedIn

Prof Frank Barry

Board Member

Stephen Elliman

Chief Scientific Officer

Stephen Elliman's LinkedIn

I am an avid stromal cell therapy developer with a habit of sitting up to 3am writing EU grants. I am passionate about developing the safest, defined and most effective stromal cell immunotherapies for patients suffering with immune mediated inflammatory diseases with unmet need. To enable this, we've developed ORBCEL at Orbsen Therapeutics.

ORBCEL is a next-gen stromal cell therapy that can be isolated from marrow or umbilical cord and ORBCEL is currently being validated and tested by 20 rigorous, independent academic research investigators around Europe and UK - as part of 6 EU, Innovate UK and Wellcome Trust funded programs.

Prof Timothy O’Brien

Board Member

Orbsen Therapeutics board members

Name & TitleBio
Larry A. Couture

Board Member

Larry A. Couture's LinkedIn

Prof Frank Barry

Board Member

Prof Timothy O’Brien

Board Member

Jack Kavanaugh

Board Member

Gerry Cuddy

Board Member

James F.x. Fahy

Board Member

Robert M. Snukal

Board Member

Orbsen Therapeutics executives FAQs

Most in demand jobs

Updated November 18, 2022

Zippia gives an in-depth look into the details of Orbsen Therapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Orbsen Therapeutics. The employee data is based on information from people who have self-reported their past or current employments at Orbsen Therapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Orbsen Therapeutics. The data presented on this page does not represent the view of Orbsen Therapeutics and its employees or that of Zippia.

Orbsen Therapeutics may also be known as or be related to ORBSEN THERAPEUTICS, Orbsen Therapeutics, Orbsen Therapeutics Limited and Orbsen Therapeutics Ltd.